Sapient Capital LLC Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Sapient Capital LLC bought a new position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the fourth quarter, HoldingsChannel reports. The fund bought 43,700 shares of the company’s stock, valued at approximately $298,000.

A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. grew its stake in shares of Y-mAbs Therapeutics by 6.4% in the first quarter. BlackRock Inc. now owns 2,945,094 shares of the company’s stock worth $34,986,000 after acquiring an additional 177,734 shares during the period. Polar Capital Holdings Plc boosted its holdings in Y-mAbs Therapeutics by 108.9% in the first quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock worth $34,187,000 after purchasing an additional 1,500,000 shares during the last quarter. State Street Corp grew its position in Y-mAbs Therapeutics by 58.5% in the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock worth $27,428,000 after purchasing an additional 852,112 shares during the period. Millennium Management LLC raised its stake in Y-mAbs Therapeutics by 4,676.0% during the 4th quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock valued at $5,508,000 after buying an additional 1,105,069 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 24.0% during the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after buying an additional 157,173 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $14.91 on Tuesday. The business has a 50-day simple moving average of $15.61 and a two-hundred day simple moving average of $9.96. Y-mAbs Therapeutics, Inc. has a 52 week low of $4.60 and a 52 week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. The company had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares in the company, valued at approximately $560,185.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 21.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. BMO Capital Markets boosted their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Canaccord Genuity Group increased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, HC Wainwright raised their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $16.57.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.